Phase III IMvigor010: Adjuvant Atezolizumab vs Observation in Patients With High-Risk Muscle-Invasive Urothelial Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Adjuvant atezolizumab did not improve disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma compared with observation.
Format: Microsoft PowerPoint (.ppt)
File Size: 253 KB
Released: June 8, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

In this short summary slideset from Clinical Care Options, a panel of international experts review the role of immunotherapy for patients with endometrial cancer.

person default Mansoor Raza Mirza, MD Bradley J. Monk, MD, FACS, FACOG Prof Isabelle Ray Coquard Released: March 8, 2021

Gain key clinical insights fast, with this short slideset from CCO on data informing current treatment for patients with bladder cancer

Andrea Apolo, MD Matthew Galsky, MD Elizabeth R. Plimack, MD, MS Released: March 3, 2021

Von Experten verfasster Kommentar zu Kombinationstherapien mit PARP-Inhibitoren und anderen Wirkstoffen bei fortgeschrittenem Prostatakrebs von Clinical Care Options (CCO)

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Commento di un esperto sulle terapie di combinazione che utilizzano inibitori PARP più altri agenti come Opzioni di cura clinica (Clinical Care Options, (CCO), nel cancro alla prostata avanzato.

Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Released: March 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue